Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502638 | 0.96 | PPARG (0.45) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2506231 | 0.94 | PPARG (0.44) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2482948 | 0.92 | LMNA (0.41) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2479074 | 0.91 | MAPT (0.47) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2502312 | 0.91 | PPARG (0.42) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2508286 | 0.89 | PPARG (0.46) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2508776 | 0.86 | MAPT (0.43) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2886746 | 0.86 | PPARG (0.46) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2506004 | 0.86 | LMNA (0.43) | LMNAGAAMAPTPOLBKMT2A | |
| SCHEMBL2501727 | 0.86 | PPARG (0.43) | LMNAGAAMAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604235-B2 | Production of substituted phenylene aromatic diesters and compositions | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2376423-A1 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | Dow Global Technologies LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100204506-A1 | Production of Substituted Phenylene Aromatic Diesters and Compositions | W. R. GRACE & CO.-CONN. | 2010-08-12 | — | — | US | disclosed |
| WO-2010078519-A1 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204506-A1 | Production of Substituted Phenylene Aromatic Diesters and Compositions | PAH, DDC, DDT | LMNA 4145/4885GAA 3079/4885MAPT 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.